Journal of Antimicrobial Chemotherapy (1999) 43, 79-86
© 1999 The British Society for Antimicrobial Chemotherapy
Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae
Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NB 68178, USA
An in-vitro pharmacokinetic model was used to compare the pharmacodynamics of levofloxacin and ciprofloxacin against four penicillin-susceptible and four penicillin-resistant Streptococcus pneumoniae.Logarithmic-phase cultures were exposed to the peak concentrations of levofloxacin or ciprofloxacin observed in human serum after 500 mg and 750 mg oral doses, human elimination pharmacokinetics were simulated, and viable bacterial counts were measured at 0, 1, 2, 4, 6, 8, 12, 24 and 36 h. Levofloxacin was rapidly and significantly bactericidal against all eight strains evaluated, with eradication of six strains occurring despite area under the inhibitory curve over 24 h (AUIC24) values of only 32– 64 SIT -1•h (serum inhibitory titre over time). The pharmacodynamics of ciprofloxacin were more variable and the rate of bacterial killing was consistently slower than observed with levofloxacin. Ciprofloxacin eradicated five strains despite having an AUIC24 of only 44 SIT-1•h. These data suggest that the increased potency of levofloxacin and more favourable pharmacokinetics compared with ciprofloxacin provide enhanced pharmacodynamic activity against S. pneumoniae. Furthermore, these data suggest that the minimum AUIC required for clinical efficacy against and eradication of S. pneumoniae with levofloxacin and ciprofloxacin may be well below the 125 SIT -1•h identified by other studies.
* Tel: +1-402-280-1881; Fax: +1-402-280-1225; E-mail: pdlister{at}creighton.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. H. Kiser, D. W. Hoody, M. D. Obritsch, C. O. Wegzyn, P. C. Bauling, and D. N. Fish Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Cazzola, M. G. Matera, G. Donnarumma, M. A. Tufano, A. Sanduzzi, F. Marchetti, and F. Blasi Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis Chest, October 1, 2005; 128(4): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Van Wart, L. Phillips, E. A. Ludwig, R. Russo, D. A. Gajjar, A. Bello, P. G. Ambrose, C. Costanzo, T. H. Grasela, R. Echols, et al. Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4766 - 4777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuhrmann, P. Schenk, W. Jaeger, S. Ahmed, and F. Thalhammer Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration J. Antimicrob. Chemother., October 1, 2004; 54(4): 780 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Bast, M. Yue, X. Chen, D. Bell, L. Dresser, R. Saskin, L. A. Mandell, D. E. Low, and J. C. S. de Azavedo Novel Murine Model of Pneumococcal Pneumonia: Use of Temperature as a Measure of Disease Severity To Compare the Efficacies of Moxifloxacin and Levofloxacin Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3343 - 3348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Florea, P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1215 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pea, F. Pavan, E. Nascimben, C. Benetton, P. G. Scotton, A. Vaglia, and M. Furlanut Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3104 - 3108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Smith Pharmacokinetic/Pharmacodynamic Considerations in Community-Acquired Lower Respiratory Tract Infections Journal of Pharmacy Practice, October 1, 2003; 16(5): 313 - 323. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials Ann. Pharmacother., October 1, 2003; 37(10): 1478 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Scaglione, J. W. Mouton, R. Mattina, and F. Fraschini Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC Ratios Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2749 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Garrison Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother., September 1, 2003; 52(3): 503 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Nicolau, H. M. Mattoes, M. Banevicius, D. Xuan, and C. H. Nightingale Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against Streptococcuspneumoniae in the Thigh Infection Model Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1630 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, and K. E. Bowker Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1088 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan and K. E. Bowker Mechanism of Fluoroquinolone Resistance Is an Important Factor in Determining the Antimicrobial Effect of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1096 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, C. M. Rubino, S. M. Bhavnani, and P. G. Ambrose Worldwide Antimicrobial Susceptibility Patterns and Pharmacodynamic Comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team Antimicrob. Agents Chemother., January 1, 2003; 47(1): 292 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Ellbogen, K. M. Olsen, M. J. Gentry-Nielsen, and L. C. Preheim Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia J. Antimicrob. Chemother., January 1, 2003; 51(1): 83 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, D. Roberts, A. Waltky, N. Laing, K. Nichol, H. Smith, A. Noreddin, T. Bellyou, and D. J. Hoban Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., May 1, 2002; 49(5): 807 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lister Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of Area under the Curve/MIC Ratios on Eradication Antimicrob. Agents Chemother., January 1, 2002; 46(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. P. Balcabao, L. Alou, L. Aguilar, M. L. Gomez-Lus, M. J. Gimenez, and J. Prieto Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones J. Antimicrob. Chemother., December 1, 2001; 48(6): 907 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Ambrose, D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2793 - 2797. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2916 - 2921. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. Malone, D. N. Fish, E. Abraham, and I. Teitelbaum Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2949 - 2954. [Abstract] [Full Text]
|
|
|
|
|
|
H. M. Mattoes, M. Banevicius, D. Li, C. Turley, D. Xuan, C. H. Nightingale, and D. P. Nicolau Pharmacodynamic Assessment of Gatifloxacin against Streptococcus pneumoniae Antimicrob. Agents Chemother., July 1, 2001; 45(7): 2092 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Lister and C. C. Sanders Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother., June 1, 2001; 47(6): 811 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, M. Walters, N. Laing, and D. J. Hoban In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., April 1, 2001; 47(4): 435 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Xuan, M. Zhong, H. Mattoes, K. Q. Bui, J. McNabb, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale Streptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model Antimicrob. Agents Chemother., March 1, 2001; 45(3): 794 - 799. [Abstract] [Full Text]
|
|
|
|
|
|
A. MacGowan, C. Rogers, and K. Bowker The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens J. Antimicrob. Chemother., August 1, 2000; 46(2): 163 - 170. [Full Text] [PDF]
|
|